Market Place
Sourcing Support
Crinetics Announces Dec 2024 Inducement Grants Under Nasdaq Rule
11 Dec 2024 //
GLOBENEWSWIRE
Crinetics to Present at December Investor Conferences
15 Nov 2024 //
GLOBENEWSWIRE
Crinetics Pharmaceuticals Showcases Neuroendocrine Tumor Data
14 Nov 2024 //
GLOBENEWSWIRE
Crinetics Pharma Reports Q3 2024 Financial Results & Update
12 Nov 2024 //
GLOBENEWSWIRE
Crinetics Showcases Neuroendocrine Tumor Pipeline at NANETS Meeting
12 Nov 2024 //
GLOBENEWSWIRE
Crinetics Announces Inducement Grants Under Nasdaq LR 5635(c)(4)
11 Nov 2024 //
GLOBENEWSWIRE
Crinetics To Report Q3 2024 Financial Results On November 12
16 Oct 2024 //
GLOBENEWSWIRE
Crinetics Announces Oct 2024 Inducement Grants Under Nasdaq Rule
10 Oct 2024 //
GLOBENEWSWIRE
Crinetics Pharmaceuticals Announces Proposed Public Offering
08 Oct 2024 //
GLOBENEWSWIRE
Crinetics Pharma Announces Pricing Of Upsized Public Stock Offering
08 Oct 2024 //
GLOBENEWSWIRE
Crinetics Submits NDA For Paltusotine For Treatment Of Acromegaly
26 Sep 2024 //
GLOBENEWSWIRE
Crinetics Announces September 2024 Inducement Grants Under Nasdaq
10 Sep 2024 //
GLOBENEWSWIRE
Crinetics Pharmaceuticals to Participate in Two Upcoming Investor Conferences
29 Aug 2024 //
GLOBENEWSWIRE
Crinetics Announces August 2024 Inducement Grants
12 Aug 2024 //
GLOBENEWSWIRE
Crinetics Launches Initiative To Raise Acromegaly Treatment Awareness
08 Aug 2024 //
GLOBENEWSWIRE
Crinetics Pharma Reports Q2 2024 Results And Business Update
08 Aug 2024 //
GLOBENEWSWIRE
Crinetics To Report Q2 2024 Financial Results On August 8
18 Jul 2024 //
GLOBENEWSWIRE
Crinetics Pharma Announces July 2024 Inducement Grants Under Nasdaq Rule
10 Jul 2024 //
GLOBENEWSWIRE
EY Announces Scott Struthers, CEO and Founder of Crinetics Pharmaceuticals
18 Jun 2024 //
GLOBENEWSWIRE
Crinetics Announces June 2024 Inducement Grants Under Nasdaq Rule
10 Jun 2024 //
GLOBENEWSWIRE
Crinetics Positions Paltusotine As Potential Acromegaly First Choice
03 Jun 2024 //
GLOBENEWSWIRE
Crinetics` Atumelnant Shows Positive CAH, ACTH-Dependent Cushing`s Data
03 Jun 2024 //
GLOBENEWSWIRE
Crinetics Appoints Robert Cuddihy As SVP Medical Affairs
30 May 2024 //
GLOBENEWSWIRE
Crinetics Releases ENDO 2024 Late-Breaking Abstracts Early
22 May 2024 //
GLOBENEWSWIRE
Crinetics` stock jumps following promising Ph2 data in four patients
22 May 2024 //
ENDPTS
Crinetics May 2024 Inducement Grants Under Nasdaq Rule
10 May 2024 //
GLOBENEWSWIRE
Crinetics Pharma Q1 2024 Financials And Business Update
09 May 2024 //
GLOBENEWSWIRE
Crinetics At ENDO On Atumelnant, Paltusotine Programs
08 May 2024 //
GLOBENEWSWIRE
Crinetics Q1 2024 Results On May 9
02 May 2024 //
GLOBENEWSWIRE
Crinetics April 2024 Inducement Grants Under Nasdaq 5635(c)(4)
11 Apr 2024 //
GLOBENEWSWIRE
Crinetics Bags Second Phase III Win for Acromegaly, Heads for NDA Submission
20 Mar 2024 //
BIOSPACE
Crinetics™Endpoints in the Phase 3 PATHFNDR-2 Study in Acromegaly Patients
19 Mar 2024 //
GLOBENEWSWIRE
Crinetics growth disorder drug sees ph. 2 carcinoid syndrome win
13 Mar 2024 //
FIERCE BIOTECH
Crinetics Announces Positive Topline Results from Phase 2 Trial of Paltusotine
12 Mar 2024 //
GLOBENEWSWIRE
Crinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11 Mar 2024 //
GLOBENEWSWIRE
Crinetics Announces Oversubscribed $350 Million Private Placement
28 Feb 2024 //
GLOBENEWSWIRE
Crinetics Reports Fourth Quarter and Full Year 2023 Financial Results
28 Feb 2024 //
GLOBENEWSWIRE
Crinetics to Report Fourth Quarter and Full Year 2023 Financial Results
14 Feb 2024 //
GLOBENEWSWIRE
Crinetics Announces 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
12 Feb 2024 //
GLOBENEWSWIRE
Crinetics Announces January 2024 Inducement Grants Under Nasdaq Rule 5635(c)(4)
10 Jan 2024 //
GLOBENEWSWIRE
Crinetics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
03 Jan 2024 //
GLOBENEWSWIRE
Crinetics Announces Positive Findings from Open-Label Phase 2 of Paltusotine
18 Dec 2023 //
GLOBENEWSWIRE
Crinetics Announces 2023 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11 Dec 2023 //
GLOBENEWSWIRE
Crinetics Pharmaceuticals to Participate in Upcoming Investor Conferences
20 Nov 2023 //
GLOBENEWSWIRE
Crinetics Announces 2023 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10 Nov 2023 //
GLOBENEWSWIRE
Crinetics Pharmaceuticals Reports Third Quarter 2023 Financial Results
07 Nov 2023 //
GLOBENEWSWIRE
Crinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10 Oct 2023 //
GLOBENEWSWIRE
Crinetics to Participate in the Cantor Global Healthcare Conference 2023
20 Sep 2023 //
GLOBENEWSWIRE
Crinetics Announces Pricing of Upsized Public Offering of Common Stock
12 Sep 2023 //
GLOBENEWSWIRE
Crinetics soars on `picture perfect` data for hormonal disorder drug
12 Sep 2023 //
REUTERS
Crinetics Pharmaceuticals Announces Proposed Public Offering Of Common Stock
11 Sep 2023 //
PRESS RELEASE
Crinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11 Sep 2023 //
GLOBENEWSWIRE
Crinetics’ Oral Paltusotine Achieved The Primary And All Secondary Endpoints
10 Sep 2023 //
PRESS RELEASE
Crinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10 Aug 2023 //
GLOBENEWSWIRE
Crinetics Pharmaceuticals Reports Second Quarter 2023 Financial Results
08 Aug 2023 //
GLOBENEWSWIRE
Crinetics blindsided by nonclinical data that sink orphan drug
08 Aug 2023 //
FIERCE BIOTECH
Crinetics Hosting Leader Webinar to Discuss the Current Treatment Landscape
31 Jul 2023 //
GLOBENEWSWIRE
Crinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10 Jul 2023 //
GLOBENEWSWIRE
New Data Demonstrating Stable Biochemical and Symptom Levels Oral Paltusotine
21 Jun 2023 //
GLOBENEWSWIRE
Crinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
12 Jun 2023 //
GLOBENEWSWIRE
